Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 Y163* |
| Therapy | Adavosertib + Carboplatin |
| Indication/Tumor Type | ovarian cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 Y163* | ovarian cancer | predicted - sensitive | Adavosertib + Carboplatin | Case Reports/Case Series | Actionable | In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 Y163* (PMID: 27998224; NCT01164995). | 27998224 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27998224) | Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months. | Full reference... |